This month’s issue highlights that Arrowhead, a US-based provider of Investor Relations services, now has released an initial financial analysis report on the company. In this report, the firm publishes a fair value bracket for Paxman of SEK 57.1-76.5 per share, compared to the share price of 42.3 SEK on January 24, 2023. The report also highlights the company’s presence in more than 60 countries, the ongoing work to convert its customers in the US to a new buy and bill model, and the upcoming phase 3 efficacy study in 2023 with SWOG Cancer Research Network and the National Cancer Institute to evaluate Paxman’s portable limb cryocompression system (PLCS) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.

The newsletter also includes information on several orders to the UK and Ireland, the United States (including signed agreements for the new buy and bill model) and a number of international markets in Asia, Europe, South America and the Middle East, that Paxman has been shortlisted for the Medilink North of England Healthcare Business Awards 2023 in the Export Achievement Award category, successful certification of a distribution partner, and that the company’s scalp cooling was featured in several US media channels.

To read the newsletter and subscribe for upcoming issues, follow this link:

https://bit.ly/paxjan23en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

For more information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se